The ESMO AI & Digital Oncology Congress 2025 programme is now online!
The ESMO AI & Digital Oncology Congress is the new forum organised by the European Society for Medical Oncology (ESMO) to provide an opportunity for scientific, methodological, regulatory, policy and industry experts to connect and interact, and to involve general cancer healthcare practitioners in discussions about AI and digital health.
The Congress will involve all stakeholders in a novel format that integrates education with the presentation of scientific breakthroughs, in-depth discussions of complex issues, and the showcasing of tools and applications that will ultimately develop a connected community of experts.
Learning objectives
- To inform oncology health care professionals on the latest scientific breakthroughs in the field of AI & Digital Oncology.
- To connect expert groups allowing for interactions accelerating the development of innovative AI solutions in oncology.
- To provide insights on transversal topics related to methodology, ethics, industry initiatives, legal and regulatory considerations on AI & Digital Oncology.
Accreditation
ESMO-MORA: The ESMO AI & Digital Oncology Congress 2025 programme will be submitted for ESMO-MORA category 1. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.
Disclaimer
ESMO is a scientific and professional, non-political and non-religious organisation. ESMO will not accept responsibility for any comments or remarks made during any of our events by session chairs, invited speakers, presenters, members or any other contributor, formally or informally, which might cause offence or be perceived as being biased.
The experts invited by ESMO as abstract Discussants are selected on an individual basis to provide their own interpretation of the data and are not acting as ESMO spokespersons.
All Speakers and Discussants are required to declare their interests, if any, and include a Declaration of Interest (DOI) slide at the start of their presentation(s).
The ESMO recommendations on the clinical utility of new drugs are only presented in the ESMO Clinical Practice Guidelines and such recommendations represent the only official position of ESMO.